Although the prevalence of cigarette smoking has significantly declined from nearly 21% of the U.S. adult population identifying as smokers in 2005 to only 14% today, an estimated 34.1 million adults still currently smoke cigarettes. In addition, many have transitioned to the use of electronic cigarettes in hopes of reducing cardiometabolic risks. However, the cardiovascular toxicity of electronic cigarettes is not well understood and comprehensive population data assessing their adverse effects remains sparse.
Researchers continue to investigate the repercussions of both cigarette and e-cigarette use, including the specific cardiovascular disease biomarkers that can act as predictive factors for CVD events. Inflammation and oxidative stress have been identified as key contributors of smoking-induced cardiovascular disease prompting scientists to evaluate these measures in current smokers. Findings recently published in Circulation reveal that similar levels of inflammation and oxidative stress biomarkers can be observed in patients who use both electronic cigarettes and cigarettes and those who exclusively smoke cigarettes.